# Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

> **NCT07360743** · PHASE2 · NOT_YET_RECRUITING · sponsor: **UNICANCER** · enrollment: 275 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer (Squamous or Non Squamous)

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT07360743
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-06
- **Final completion:** 2032-04
- **Target enrollment:** 275 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07360743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07360743, "Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07360743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*